




RealRate

PHARMACEUTICAL 2020

Collegium Pharmaceutical INC
Rank 228 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Collegium Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Collegium Pharmaceutical INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Collegium Pharmaceutical INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 118% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 38% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	255,720
Cost of Goods Sold	193,660
Intangible Assets	0
Liabilities, Current	201,765
Liabilities, Non-Current	9,438
Other Assets	38,728
Other Compr. Net Income	0
Other Expenses	909
Other Liabilities	7,667
Other Net Income	1,935
Other Revenues	296,701
Property and Equipment	11,854
Research and Development	10,340
Selling, General and Administrative Expense	116,449

Output Variable	Value in 1000 USD
Assets	306,302
Liabilities	218,870
Expenses	321,358
Revenues	296,701
Stockholders Equity	87,432
Net Income	-22,722
Comprehensive Net Income	-22,722
BaseVar	572,583
ECR before LimitedLiability	64%
Economic Capital Ratio	200%